Hyzmed

Hyzmed Best Medical Product Supplier

Cotton Roll Bandage
05/01/2026

Cotton Roll Bandage

Happy New Year
31/12/2025

Happy New Year

Crepe Bandage
30/12/2025

Crepe Bandage

Conforming Bandage
26/12/2025

Conforming Bandage

Merry Christmas🎄🎄🎄HYZ medical equipment has experienced several Christmas festival with our partners all over the world....
24/12/2025

Merry Christmas🎄🎄🎄HYZ medical equipment has experienced several Christmas festival with our partners all over the world. And Hope in the future we can continue to offer cost-effective,cutting-edage and environmental medical product, contributing a healthy, green, and warm medical environment.

Merry Christmas and Happy New Year!
24/12/2025

Merry Christmas and Happy New Year!

TIL Therapy’s 10-Year Cancer Remission BreakthroughA 2025 SITC study revealed two metastatic cervical cancer patients ac...
18/12/2025

TIL Therapy’s 10-Year Cancer Remission Breakthrough
A 2025 SITC study revealed two metastatic cervical cancer patients achieved 10-year cancer-free survival after single TIL therapy. This autologous cell therapy, using patients’ own tumor-infiltrating lymphocytes, proves durable efficacy in tough-to-treat solid tumors.
It’s a game-changer for refractory cancers, offering curative hope beyond standard treatments. Wider accessibility and larger trials will further unlock its potential.

HMEF
16/12/2025

HMEF

A-2-3 three crank manual bed
10/12/2025

A-2-3 three crank manual bed

Closed Suction Cathether
08/12/2025

Closed Suction Cathether

Blinatumomab's New Approval for B-cell Precursor ALLRecently, the FDA approved blinatumomab as a post-transplant mainten...
03/12/2025

Blinatumomab's New Approval for B-cell Precursor ALL
Recently, the FDA approved blinatumomab as a post-transplant maintenance therapy for adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia (ALL) who are in complete remission but at high risk of relapse. This marks a crucial advancement in reducing relapse rates for high-risk ALL patients after transplantation.
The approval is a big win for targeted immunotherapy. Blinatumomab, a bispecific T-cell engager, effectively directs the body’s immune system to attack residual leukemia cells that standard treatments might miss. For patients facing the fear of relapse post-transplant, this therapy offers a much-needed layer of protection and hope for long-term survival.
Yet, accessibility remains a challenge. The high cost of such targeted drugs may put them out of reach for many patients globally. Wider access and cost-control measures are needed to let more people benefit from this medical progress.

Thank you so much for your support and partnership. May you happy Thanksgiving
27/11/2025

Thank you so much for your support and partnership. May you happy Thanksgiving

Address

Room 2209-2210, New World Business Center, Min’an Road, Yinzhou District
Ningbo

Telephone

+8613857407522

Website

Alerts

Be the first to know and let us send you an email when Hyzmed posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Hyzmed:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category